OVID — Ovid Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $116.79m
- $91.19m
- $0.57m
- 31
- 13
- 99
- 45
Annual income statement for Ovid Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.6 | 208 | 1.5 | 0.392 | 0.566 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 94 | 84.2 | 57.1 | 59.7 | 62.5 |
| Operating Profit | -81.4 | 124 | -55.5 | -59.3 | -61.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -81 | 124 | -54.2 | -52.3 | -26.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -81 | 123 | -54.2 | -52.3 | -26.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -81 | 123 | -54.2 | -52.3 | -26.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -81 | 120 | -54.2 | -52.3 | -26.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.39 | 1.76 | -0.769 | -0.742 | -0.373 |